(Q38127585)

29 August 2017

title

Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults (English)

1 reference

29 August 2017

1 reference

1

Lily P H Yang

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1357-1366

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0103-6

29 August 2017

exact match

0 references

cites work

Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Cost Effectiveness of Influenza Vaccination in Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Economic value of influenza vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Annual influenza vaccination: offering protection beyond infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Insect cell technology is a versatile and robust vaccine manufacturing platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Recombinant protein vaccines produced in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

FluBlok, a next generation influenza vaccine manufactured in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

FluBlok, a recombinant hemagglutinin influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0103-6

Safety testing and use of insect cells for recombinant protein production.

21 January 2018

1 reference

12 December 2020

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old

1 reference

12 December 2020

Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).

1 reference

12 December 2020

A fast track influenza virus vaccine produced in insect cells

1 reference

12 December 2020

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season

1 reference

12 December 2020

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

1 reference

12 December 2020

Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States

1 reference

12 December 2020

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

1 reference

12 December 2020

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

1 reference

12 December 2020

FluBlok, a recombinant influenza vaccine

1 reference

12 December 2020

Influenza neuraminidase as a vaccine antigen

1 reference

12 December 2020

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010

1 reference

12 December 2020

10.1007/S40265-013-0103-6

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1010359717

0 references

1 reference